Fig. 2: Somatic mutation landscape of mPDAC detected using liquid biopsy (ctDNA) sequencing at baseline. | Nature Communications

Fig. 2: Somatic mutation landscape of mPDAC detected using liquid biopsy (ctDNA) sequencing at baseline.

From: The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma

Fig. 2

A Oncoprint depicting most frequently mutated genes detected by baseline ctDNA sequencing in the cohort of 173 patients with mPDAC. Upper bars indicate blood tumor mutation burden (TMB; mut/Mb) levels and are colored based on microsatellite instability (red) or stable (grey) status. B Histogram with overlaid density curve showing distribution of blood tumor mutational burden levels across the cohort. C Histogram with overlaid density curve showing distribution of the number of SNV/indels detected by ctDNA sequencing. Source data are provided as a source data file.

Back to article page